BIOHAVEN LTD (BHVN:NYSE)
$11.01 0.77 (7.5195%)
Analysed BIOHAVEN LTD (BHVN:NYSE) News Sources
Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying
12-04-2026
yahoo.com
Why Biohaven Stock Crushed it on Monday
13-04-2026
fool.com
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
20-04-2026
yahoo.com
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)
22-04-2026
yahoo.com
KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen Therapeutics
28-04-2026
yahoo.com
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
04-05-2026
yahoo.com
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans
05-05-2026
yahoo.com
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
05-05-2026
yahoo.com
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed
06-05-2026
yahoo.com
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
26-05-2026
yahoo.com
What is the current price of BIOHAVEN LTD (BHVN:NYSE)?
The current price of BIOHAVEN LTD (BHVN:NYSE) is $11.01.
BIOHAVEN LTD (BHVN:NYSE) absolute price change since previous trading day?
The absolute price change of BIOHAVEN LTD (BHVN:NYSE) since the previous trading day is $0.77.
BIOHAVEN LTD (BHVN:NYSE) percentage price change since previous trading day?
The percentage price change of BIOHAVEN LTD (BHVN:NYSE) since the previous trading day is 7.5195%.
What is the most recent average sentiment score for BIOHAVEN LTD (BHVN:NYSE)?
The most recent average sentiment score for BIOHAVEN LTD (BHVN:NYSE) is 88 out of 100.
What is the most recent average sentiment for BIOHAVEN LTD (BHVN:NYSE)?
The most recent sentiment for BIOHAVEN LTD (BHVN:NYSE) is .
SEC-8K** Filing Available For BIOHAVEN LTD (BHVN:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.